-
,for, Item ID-
- #1233499
- BD #256097
Respiratory Test Kit BD Veritor™ System SARS-CoV-2 / Influenza A + B 150 Tests CLIA Waived
PROMO PKG, SARS-COV-2 & FLU VALUE PK (EA=5KT/150TEST/KT)
Features
- Value Pack of 5 BD Veritor™ Rapid Detection of SARS-CoV-2 & Flu A+B kits
- Product ships with minimum 30 days dating
- BD Veritor System for Rapid Detection of SARS-CoV-2 and Flu A+B is For use under an Emergency Use Authorization only: https://www.fda.gov/medical-devices/covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2 for use at the Point of Care (POC), i.e., i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation
- More …
Product Details Email
Product Specifications
McKesson # | 1233499 |
---|---|
Manufacturer # | 256097 |
Brand | BD Veritor™ System |
Manufacturer | BD |
Country of Origin | Unknown |
Application | Respiratory Test Kit |
CLIA Classification | CLIA Waived |
CLIA Classified | CLIA Waived |
Contents 1 | (5) Kits each containing: (30) Single Use Test Devices, (30) Single Use Reaction Tubes with 400 µL Reagent, (30) Sterile Single Use Sampling Swabs, 1 Positive SARS-CoV-2 Control Swab, 1 Positive Flu A Control Swab, 1 Positive Flu B Control Swab, (3) Paperboard Tube Stands, IFU, Quick Ref Card, and Nasal Sampling Guide |
For Use With | For BD Veritor™ Plus System |
Number of Tests | 150 Tests |
Purchase Program Type | Promotion |
Reading Type | Machine Read |
Sample Type | Nasal Swab Sample |
Specialty | Immunoassay |
Test Format | Test Device Format |
Test Kit Type | Rapid |
Test Method | Chromatographic Digital Immunoassay |
Test Name | SARS-CoV-2 / Influenza A + B |
Test Type | Antigen Detection |
Time to Results | 15 Minute Results |
UNSPSC Code | 41116144 |
Features
- Value Pack of 5 BD Veritor™ Rapid Detection of SARS-CoV-2 & Flu A+B kits
- Product ships with minimum 30 days dating
- BD Veritor System for Rapid Detection of SARS-CoV-2 and Flu A+B is For use under an Emergency Use Authorization only: https://www.fda.gov/medical-devices/covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2 for use at the Point of Care (POC), i.e., i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation
- BD Triplex assay requires Veritor™ System firmware version 5.5 or greater; firmware version info is displayed on screen when turning on the analyzer or on the orange sticker if it is attached to the analyzer
- This test is authorized for use at the Point of Care (POC), i.e., i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditationtories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate, high, or waived complexity tests
- Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate, high, or waived complexity tests
- The test is intended to be used with direct nasal swabs and is not validated for use with swabs in viral transport media
- Kit configured for testing anterior nasal swab samples freshly collected, processed, and dispensed directly onto assay test device
- Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status
- Laboratories within the United States and its territories are required to report all SARS-CoV-2 results to the appropriate public health authorities
- Negative results should be treated as presumptive, do not rule out either Influenza or SARS-CoV-2, and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions
- Negative results for SARS-CoV-2 should be confirmed with a molecular assay, if necessary, for patient management
- Time to result: 15 minutes, test device can be read at 15 minutes but no later than 20 minutes
- Materials Required but not provided: BD Veritor™ Plus Analyzer running firmware v5.50 or later (Cat. No. 256066)
- This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens
More Information
- BD Veritor System COVID-19 and Flu A+B FDA EUA Letter
- BD Veritor System COVID-19 and Flu A+B IFU
- BD Veritor System COVID-19 and Flu A+B Patients Fact Sheet
- BD Veritor System COVID-19 and Flu A+B Customer Letter April 2021
- BD Veritor System COVID-19 and Flu A+B Healthcare Providers Fact Sheet
- BD Veritor System COVID-19 and Flu A+B Sales Sheet
- BD Veritor Systems SARS-CoV-2 Variants July 2021
Professionals Also Viewed
-
,for, Item ID-
- #1076728
- Providers like you icon 5,830
- McKesson Brand #181-36025
- Rapid qualitative test that detects Influenza type A and type B antige …
- Color-coded control swab packaging for easy positive/negative identifi …
- Results in under 15 minutes
-
,for, Item ID-
- #951316
- Providers like you icon 5,505
- McKesson Brand #5003
- A rapid test for the qualitative detection of Strep A antigen in throa …
- CLIA waived and easy to use
- Contents: 25 Dipsticks (in sealed pouches), Disposable extraction test …
-
,for, Item ID-
- #951312
- Providers like you icon 4,549
- McKesson Brand #4999
- A rapid test for the qualitative detection of Strep A antigen in throa …
- CLIA waived and easy to use
- Contents: 50 Dipsticks (2 vials of 25), Disposable extraction test tub …
-
,for, Item ID-
- #1127458
- Providers like you icon 464
- McKesson Brand #181-34125
- A rapid test for the qualitative detection of Strep A antigen in throa …
- Easy-to-use flip step eliminates need for pipetting
- Fast, accurate detection of Group A Strep with walk-away convenience